Related Experiment Video
Updated: Jan 16, 2026
Pseudomonas aeruginosa Induced Lung Injury Model
Published on: October 29, 2014
Furin Inhibition Protects Against Acute Lung Injury in a Mouse Model of Pseudomonas Aeruginosa Infection
Abstract:
Pseudomonas aeruginosa (PA) is responsible for significant morbidity and mortality particularly in patients with chronic lung diseases such as chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF) as well as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). The rise of antibiotic-resistant PA strains necessitates alternative treatment strategies. Among the different toxins secreted by PA, Exotoxin-A (Exo-A) becomes cytotoxic when cleaved by furin. This study investigates the therapeutic potential of furin inhibitor BOS-318 in mitigating acute lung injury induced by Exo-A and PA infection. Furin inhibition significantly improved survival rates and reduced lung injury in mouse pneumonia models using Exo-A and PA103. Additionally, BOS-318 accelerated bacterial clearance in vivo, and increased phagocytosis by alveolar macrophages. Bulk RNA-seq immune profiling revealed modulation of the natural killer (NK) cell signaling pathway possibly due to a decrease in NK recruitment, suggesting a role of furin in shaping the immune response. Overall, our findings demonstrate that furin inhibition protects against PA-induced acute lung injury and hastens bacterial clearance. These results are the first to characterize furin inhibition in animal models and supports its potential use as an adjunctive therapeutic strategy for treating PA infections.
Insights
Furin inhibition with BOS-318 protects against Pseudomonas aeruginosa lung injury and infection. This approach improves survival, reduces lung damage, and aids bacterial clearance in animal models.
Area of Science:
- Infectious Diseases
- Pulmonology
- Pharmacology
Background:
- Pseudomonas aeruginosa (PA) causes significant lung disease and mortality, especially in vulnerable populations.
- Antibiotic resistance in PA necessitates novel therapeutic strategies.
- Exotoxin-A (Exo-A) from PA is cytotoxic upon furin cleavage, contributing to lung injury.
Purpose of the Study:
- To investigate the therapeutic potential of the furin inhibitor BOS-318.
- To evaluate BOS-318's efficacy in mitigating acute lung injury caused by Exo-A and PA infection.
Main Methods:
- Utilized mouse pneumonia models infected with Exo-A and PA103.
- Administered the furin inhibitor BOS-318.
- Assessed survival rates, lung injury, bacterial clearance, and phagocytosis by alveolar macrophages.
- Performed bulk RNA-sequencing for immune profiling.
Main Results:
- Furin inhibition significantly improved survival rates and reduced lung injury in mouse models.
- BOS-318 accelerated bacterial clearance in vivo.
- Enhanced phagocytosis by alveolar macrophages was observed.
- Immune profiling indicated modulation of natural killer (NK) cell signaling pathways.
Conclusions:
- Furin inhibition is a promising adjunctive therapeutic strategy for PA infections.
- BOS-318 demonstrates protective effects against PA-induced acute lung injury.
- This study provides the first characterization of furin inhibition in animal models for PA infections.
